| 0.67 -0.033 (-4.73%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.43  |
1-year : | 1.84 |
| Resists | First : | 1.23 |
Second : | 1.58 |
| Pivot price | 0.84 |
|||
| Supports | First : | 0.67 |
Second : | 0.55 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.89 |
| MA(100) : | 1.55 |
MA(250) : | 2.16 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.1 |
D(3) : | 2.9 |
| RSI | RSI(14): 23.1 |
|||
| 52-week | High : | 3.9 | Low : | 0.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CUE ] has closed above bottom band by 8.6%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.73 - 0.73 | 0.73 - 0.73 |
| Low: | 0.66 - 0.66 | 0.66 - 0.67 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Fri, 26 Jul 2024
Cue Biopharma downsizes to focus on autoimmune pipeline - Clinical Trials Arena
Fri, 26 Jul 2024
Cue Biopharma downsizes to focus on autoimmune pipeline - Yahoo Finance
Fri, 26 Jul 2024
Boston biotech firm lays off 25% of its staff, cuts CEOs salary - NBC Boston
Thu, 25 Jul 2024
Cue Biopharma Refocuses on Autoimmune Programs, Restructures Operations - TipRanks
Thu, 25 Jul 2024
Cue Biopharma Announces Strategic Prioritization of - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 34.2 (%) |
| Shares Short | 4,740 (K) |
| Shares Short P.Month | 4,350 (K) |
| EPS | -1.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 0 % |
| Operating Margin | -737.8 % |
| Return on Assets (ttm) | -47.3 % |
| Return on Equity (ttm) | -117.5 % |
| Qtrly Rev. Growth | 818.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.14 |
| EBITDA (p.s.) | -1.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | 1.08 |
| Price to Sales | 4.64 |
| Price to Cash Flow | -0.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|